PE20020386A1 - Derivados de tetrazolil-fenil acetamida como activadores de glucoquinasa - Google Patents

Derivados de tetrazolil-fenil acetamida como activadores de glucoquinasa

Info

Publication number
PE20020386A1
PE20020386A1 PE2001000814A PE2001000814A PE20020386A1 PE 20020386 A1 PE20020386 A1 PE 20020386A1 PE 2001000814 A PE2001000814 A PE 2001000814A PE 2001000814 A PE2001000814 A PE 2001000814A PE 20020386 A1 PE20020386 A1 PE 20020386A1
Authority
PE
Peru
Prior art keywords
glucokinase activators
phenyl
tetrazolil
cyclopentil
tetrazol
Prior art date
Application number
PE2001000814A
Other languages
English (en)
Spanish (es)
Inventor
Achyutharao Sidduri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20020386A1 publication Critical patent/PE20020386A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2001000814A 2000-08-15 2001-08-15 Derivados de tetrazolil-fenil acetamida como activadores de glucoquinasa PE20020386A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22549400P 2000-08-15 2000-08-15

Publications (1)

Publication Number Publication Date
PE20020386A1 true PE20020386A1 (es) 2002-05-13

Family

ID=22845106

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000814A PE20020386A1 (es) 2000-08-15 2001-08-15 Derivados de tetrazolil-fenil acetamida como activadores de glucoquinasa

Country Status (20)

Country Link
US (3) US6369232B1 (enExample)
EP (1) EP1311504B1 (enExample)
JP (1) JP3961948B2 (enExample)
KR (1) KR100518061B1 (enExample)
CN (1) CN1209362C (enExample)
AR (1) AR031718A1 (enExample)
AT (1) ATE297921T1 (enExample)
AU (2) AU2001283998B2 (enExample)
BR (1) BR0113312A (enExample)
CA (1) CA2419416C (enExample)
DE (1) DE60111540T2 (enExample)
DK (1) DK1311504T3 (enExample)
ES (1) ES2243541T3 (enExample)
MX (1) MXPA03001275A (enExample)
PA (1) PA8525201A1 (enExample)
PE (1) PE20020386A1 (enExample)
PT (1) PT1311504E (enExample)
UY (1) UY26885A1 (enExample)
WO (1) WO2002014312A1 (enExample)
ZA (1) ZA200300904B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
US7078423B2 (en) * 2002-07-18 2006-07-18 Inotek Pharmaceuticals Corporation 5-Aryltetrazole compounds, compositions thereof, and uses therefor
US7087631B2 (en) * 2002-07-18 2006-08-08 Inotek Pharmaceuticals Corporation Aryltetrazole compounds, and compositions thereof
PL375021A1 (en) * 2002-10-03 2005-11-14 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
MY141521A (en) 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
AU2003294376A1 (en) * 2003-01-06 2004-08-10 Eli Lilly And Company Heteroaryl compounds
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
US7262196B2 (en) * 2003-02-11 2007-08-28 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
BRPI0509543A (pt) * 2004-04-02 2007-09-18 Novartis Ag derivados de tiazolopiridina, condições farmacêuticas que contêm os mesmos e métodos para tratar condições mediadas por glucocinase
WO2005095418A1 (en) * 2004-04-02 2005-10-13 Novartis Ag Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of type 2 diabetes
EP2305674A1 (en) 2005-07-09 2011-04-06 AstraZeneca AB Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
AU2006267387B2 (en) 2005-07-11 2010-11-18 Mitsubishi Tanabe Pharma Corporation An oxime derivative and preparations thereof
JPWO2007026761A1 (ja) 2005-08-31 2009-03-12 アステラス製薬株式会社 チアゾール誘導体
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
AU2006299091A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
GT200600429A (es) * 2005-09-30 2007-04-30 Compuestos organicos
GT200600428A (es) * 2005-09-30 2007-05-21 Compuestos organicos
CA2626475A1 (en) * 2005-11-03 2007-05-10 Prosidion Limited Tricyclo substituted amides
JP2009515997A (ja) * 2005-11-18 2009-04-16 タケダ サン ディエゴ インコーポレイテッド グルコキナーゼ活性剤
BRPI0619980A2 (pt) * 2005-12-15 2014-10-14 Nihon Nohyaku Co Ltd Derivados de ftalamida e de anilina, inseticida agrícola ou hortícula, e, método de uso do mesmo
EP2001875A2 (en) 2006-03-08 2008-12-17 Takeda San Diego, Inc. Glucokinase activators
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
WO2007143434A2 (en) * 2006-05-31 2007-12-13 Takeda San Diego, Inc. Indazole and isoindole derivatives as glucokinase activating agents
US7910747B2 (en) * 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
US7902248B2 (en) 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
JP5419706B2 (ja) 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
TW200831081A (en) * 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
US8314247B2 (en) * 2007-01-10 2012-11-20 Mitsubishi Tanabe Pharma Corporation Hydrazone derivative
CN101687800B (zh) * 2007-03-07 2012-03-21 杏林制药株式会社 葡糖激酶活化物质
US8173645B2 (en) * 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
AU2008310519B2 (en) * 2007-10-08 2013-05-02 Advinus Therapeutics Private Limited Acetamide derivatives as glucokinase activators, their process and medicinal applications
AR070107A1 (es) * 2008-01-15 2010-03-17 Lilly Co Eli R-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida en forma cristalina, composicion farmaceutica que la comprende y su uso para la manufactura de un medicamento util para la prevencion o tratamiento de hiperglicemia
JP5287730B2 (ja) 2008-01-18 2013-09-11 アステラス製薬株式会社 フェニルアセトアミド誘導体
AU2009241137B2 (en) * 2008-04-28 2013-10-03 Kyorin Pharmaceutical Co., Ltd. Cyclopentylacrylic acid amide derivative
CN102959076B (zh) 2010-03-31 2015-09-16 斯克里普斯研究所 重编程细胞

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3776917A (en) * 1972-06-05 1973-12-04 Schering Corp 2-amino-6-phenalkyl-aminopyridines and derivatives thereof
GB8909574D0 (en) 1989-04-26 1989-06-14 Ici Plc Chemical process
US5859052A (en) * 1993-01-14 1999-01-12 G. D. Searle & Co. Fatty acid analogs and prodrugs
US5461049A (en) * 1994-05-27 1995-10-24 Warner-Lambert Company Amide tetrazole ACAT inhibitors
US5468867A (en) * 1994-05-27 1995-11-21 Syntex (U.S.A.) Inc. Process for preparing1-butyl-2-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl1-1H-indole-3-carboxylic acid
WO1998032753A1 (en) * 1997-01-28 1998-07-30 Merck & Co., Inc. THIAZOLE BENZENESULFONAMIDES AS β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY
SI1169312T1 (en) * 1999-03-29 2005-02-28 F. Hoffmann-La Roche Ag Glucokinase activators

Also Published As

Publication number Publication date
US20020035267A1 (en) 2002-03-21
AU2001283998B2 (en) 2005-10-20
JP3961948B2 (ja) 2007-08-22
AU8399801A (en) 2002-02-25
BR0113312A (pt) 2003-07-01
US20020065275A1 (en) 2002-05-30
JP2004506632A (ja) 2004-03-04
KR100518061B1 (ko) 2005-09-28
KR20030022408A (ko) 2003-03-15
WO2002014312A1 (en) 2002-02-21
CN1209362C (zh) 2005-07-06
ES2243541T3 (es) 2005-12-01
CA2419416C (en) 2009-10-13
ATE297921T1 (de) 2005-07-15
MXPA03001275A (es) 2003-06-30
DK1311504T3 (da) 2005-10-17
US6369232B1 (en) 2002-04-09
ZA200300904B (en) 2004-04-30
DE60111540D1 (de) 2005-07-21
AR031718A1 (es) 2003-10-01
PA8525201A1 (es) 2002-07-30
EP1311504A1 (en) 2003-05-21
US6388088B1 (en) 2002-05-14
PT1311504E (pt) 2005-10-31
EP1311504B1 (en) 2005-06-15
DE60111540T2 (de) 2006-03-16
US20020035266A1 (en) 2002-03-21
US6441180B1 (en) 2002-08-27
CN1466584A (zh) 2004-01-07
CA2419416A1 (en) 2002-02-21
UY26885A1 (es) 2002-02-28

Similar Documents

Publication Publication Date Title
PE20020386A1 (es) Derivados de tetrazolil-fenil acetamida como activadores de glucoquinasa
PE20011310A1 (es) Alquinil fenil amidas heteroaromaticas como activadores de la glucokinasa
PE20020056A1 (es) Fenil amidas para-aril o heteroaril sustituidas como activadores de la glucoquinasa
PE20030968A1 (es) Derivados de 5-feniltiazol como inhibidores de cinasas
AR041467A1 (es) Indol-3-carboxamidas como activadores de glucoquinasa (gk)
PE20020593A1 (es) Activadores de glucocinasa del tipo isoindolin-2-ona
PE20030703A1 (es) Inhibidores de la 17b-hidroxiesteroide deshidrogenasa tipo 3
PE20020049A1 (es) Fenilamidas para amina sustituidas como activadores de glucoquinasa
AR032752A1 (es) Ureido propionamidas o propionamidas heteroaromaticas trans olefinicas 2,3-di-sustituidas, un proceso para su preparacion, composiciones farmaceuticas que los comprenden y el uso de las mismas para la manufactura de un medicamento como activadores de glucoquinasa
PE20011313A1 (es) Activadores de glucoquinasa que contienen hidantoina
PE20021066A1 (es) Amidas de acidos antranilicos con cadena lateral de heteroarilsulfonilo, procedimiento para su preparacion, asi como preparados farmaceuticos que las contienen
PE20020589A1 (es) 5-espiropirimidin-2,4,6-triona como inhibidores de metaloproteinasas
PE20210040A1 (es) Moduladores de la via de estres integrada
AR046244A1 (es) Activadores de glucoquinasa heteroaromaticos de seis miembros 5- sustituidos
PE20030704A1 (es) Derivados de pirrolidina
PE20020504A1 (es) N-acilsulfonamidas promotoras de apoptosis
PE20020335A1 (es) Acetamida de benceno de alfa-acil- y alfa-heteroatomo-sustituido como activadores de la glucoquinasa
RU2013138834A (ru) N-[3-(5-амино-3,3а,7,7а-тетрагидро-1н-2,4-диокса-6-аза-инден-7-ил)-фенил]-амиды в качестве ингибиторов васе1 и(или) васе2
PE20090709A1 (es) Compuestos heterociclico de 5 miembros
AR062409A1 (es) Compuesto y composicion farmaceutica, utiles como agentes terapeuticos en el tratamiento, prevencion o mejoramiento de enfermedad o trastorno caracterizado por depositos o niveles de b-amiloide elevados o para inhibir o elucidar la enzima b-secretasa, y proceso para la preparacion del compuesto
PE20020220A1 (es) Compuestos de nitrilo de dipeptido como inhibidores de catepsina k
PE20040987A1 (es) Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf)
AR038476A1 (es) Derivados de quinazolina
MY136926A (en) Glucokinase activators
AR078201A1 (es) Compuestos de 2-piridona y su uso en el tratamiento de enfermedades mediadas por la elastasa de neutrofilos

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed